Prima in high-level licensing talks
18 February, 2002 by Tanya HollisPrima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Prima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Injectable tech for fresh produce could extend shelf life
Manufacturing most impacted by ransomware in Q1 2025
Balancing packaging waste and food waste through data-driven design
Call for comment on thermolysin as a processing aid
No kidding: Australia's goatmeat exports at all-time high
CeMAT 2025 incorporates processing, packaging and more
WA Government investing $500 million to unlock industrial areas
Homegrown solar pioneer first to be funded for Solar Sunshot
Researchers show robots how to identify an object's properties through handling
UAE-funded consortium to build a waste-to-energy facility in Parkes
Digital displays in health care: benefits for patients and staff
Doctors' warning — Bupa's plans risk a US-style health model
NSWNMA: Proposed workers comp changes a "cruel blow"
Nursing and Midwifery Board waives renewal late fee until 15 June
Victoria's 2025–26 State Budget claims frontline care record